...it is apparent to this long also, especially when Anavex comes close to their first approval and what a great thought out post!
I believe even if avxl did run the proper P3 Alz trial with a positive readout, would be in the same spot as today possibly delayed by a surprise safety study requirement or something #bureaucracy. The potential of maintaining the 1B+ market cap would have been preserved by running the trial though in my humble opinion. Perhaps Missling was played by the EMA, regardless it does not excuse the poor trial designs (RETT) of the past. He has never delivered any great news, just continuously pr's validating scientific data The fact now exists that Anavex is in a group of biotechs that are addressing upstream approaches to treating CNS. When one advances on positive news, it will effect the group. I believe all of these players will partner at some point and their valuations will dramatically increase, just not to the lofty numbers as if there was one golden egg. Yes Dr Missling, deliver great FDA news soon and perhaps start a new trial.
Happy Easter!
Market Data 
Markets 
